Harbour Investments’s Vanda Pharmaceuticals VNDA Stock Holding History

Harbour Investments’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-265	Closed	-$1.27K	–	3668
2024 Q4	$1.27K	Hold	265	–	–	﹤0.01%	3121
2024 Q3	$1.24K	Hold	265	–	–	﹤0.01%	3049
2024 Q2	$1.5K	Hold	265	–	–	﹤0.01%	2893
2024 Q1	$1.09K	Hold	265	–	–	﹤0.01%	2913
2023 Q4	$1.12K	Hold	265	–	–	﹤0.01%	2802
2023 Q3	$1.15K	Hold	265	–	–	﹤0.01%	2675
2023 Q2	$1.75K	Hold	265	–	–	﹤0.01%	2578
2023 Q1	$1.8K	Hold	265	–	–	﹤0.01%	2581
2022 Q4	$1.96K	Hold	265	–	–	﹤0.01%	2521
2022 Q3	$3K	Hold	265	–	–	﹤0.01%	2365
2022 Q2	$3K	Buy	+265	New	+$2.75K	﹤0.01%	2365
2021 Q4	$4K	Sell	265 -2,356	-90%	-$41.1K	﹤0.01%	2269
2021 Q3	$45K	Buy	2,621 +46	+2%	+$806	﹤0.01%	1834
2021 Q2	$55K	Buy	2,575 +330	+15%	+$5.91K	﹤0.01%	1767
2021 Q1	$34K	Buy	+2,245	New	+$36.3K	﹤0.01%	1905

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Harbour Investments's VNDA Position: Q1 2025 in Review

Harbour Investments sold out of Vanda Pharmaceuticals (VNDA) in Q1 2025, closing a stake of 265 shares — an estimated $1.27K sold.

Harbour Investments first reported a position in VNDA in Q1 2021 and held it in 15 quarters. The position peaked at $55K in Q2 2021. 146 funds tracked by Wall St. Rank hold VNDA as of Q1 2025.

Harbour Investments reported no remaining Vanda Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Harbour Investments sold 265 Vanda Pharmaceuticals shares in Q1 2025, an estimated $1.27K.
Harbour Investments first reported a position in Vanda Pharmaceuticals in Q1 2021 and held it in 15 quarters.
Harbour Investments's Vanda Pharmaceuticals position peaked at $55K in Q2 2021.
146 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2025.

Based on Harbour Investments's 13F filing for Q1 2025, filed 8 May 2025.